Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

UCSD study finds a developmental drug targets hard-to-teach leukemia stem cells responsible for relapses

  • Posted: January 18, 2013

Researchers at the University of California, San Diego School of Medicine and the Moores Comprehensive Cancer Center have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive – and thus vulnerable – to a novel cancer stem cell-targeting drug currently under development. The findings, published in the January 17 online issue of Cell Stem Cell, open the possibility that diseases like chronic myeloid leukemia (CML) and some solid tumor cancers might – in  combination with other therapies – be more effectively treated  with this drug, and with a lower chance of relapse.

Click here to read full press release.


NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.